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This study investigated the effects of two sodium bicarbonate (NaHCO3) doses on estimated 31 
energy system contribution and performance during an intermittent high-intensity cycling test 32 
(HICT), and time-to-exhaustion (TTE) exercise. Twelve healthy males (stature: 1.75 ± 0.08 33 
m; body mass: 67.5 ± 6.3 kg; age: 21.0 ± 1.4 years; maximal oxygen consumption: 45.1 ± 7.0 34 
ml.kg.min-1) attended four separate laboratory visits. Maximal aerobic power (MAP) was 35 
identified from an incremental exercise test. During the three experimental visits, participants 36 
ingested either 0.2 g.kg-1 BM NaHCO3 (SBC2), 0.3 g.kg
-1 BM NaHCO3 (SBC3), or 0.07 37 
g.kg-1 BM sodium chloride (placebo; PLA) at 60 minutes pre-exercise. The HICT involved 3 38 
x 60 s cycling bouts (90%, 95%, 100% MAP) interspersed with 90 s recovery, followed by 39 
TTE cycling at 105% MAP. Blood lactate was measured after each cycling bout to calculate 40 
estimates for glycolytic contribution to exercise. Gastrointestinal (GI) upset was quantified at 41 
baseline, 30 minutes and 60 minutes post-ingestion, and 5 minutes post-exercise. Cycling 42 
TTE increased for SBC2 (+20.2 s; p =0.045) and SBC3 (+31.9 s; p =0.004) compared to PLA. 43 
Glycolytic contribution increased, albeit non-significantly, during the TTE protocol for SBC2 44 
(+7.77 kJ; p =0.10) and SBC3 (+7.95 kJ; p =0.07) compared to PLA. GI upset was 45 
exacerbated post-exercise after SBC3 for nausea compared to SBC2 and PLA (p <0.05), 46 
whilst SBC2 was not significantly different to PLA for any symptom (p >0.05). Both 47 
NaHCO3 doses enhanced cycling performance and glycolytic contribution, however, higher 48 
doses may maximise ergogenic benefits. 49 
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  53 
Introduction 54 
High-intensity interval training (HIIT) involves near maximal exercise bouts (>80-100% 55 
maximum heart rate) separated by brief recovery periods (Islam et al., 2017). The high 56 
anaerobic demand associated with maximal efforts results in the accumulation of hydrogen 57 
cations (H+) within the cytosol (Allen et al., 2008). Whilst these are mostly removed by 58 
intramuscular and/or extracellular buffering mechanics, production overwhelms 59 
neutralisation and this contributes towards a reduced intramuscular pH (Sahlin, 2014), 60 
causing exercise-induced acidosis. Such a biochemical state has been suggested to reduce 61 
glycolytic energy production and may disrupt calcium ion cross-bridge formation (Fitts, 62 
2016). A common strategy to mitigate these deleterious effects of exercise is to enhance 63 
circulating level of extracellular blood bicarbonate (HCO3
-), which subsequently allows for 64 
sustained efflux of H+ from intramuscular environments during high-intensity exercise 65 
(Siegler et al., 2016). Increases in [HCO3
-] of ~5.0-6.0 mmol.l-1 are suggested to be ergogenic 66 
and can be achieved via the ingestion of extracellular buffers, such as sodium bicarbonate 67 
(NaHCO3) in doses of 0.2-0.3 g.kg
-1 BM, respectively (Carr et al., 2011; Jones et al., 2016). 68 
Common practice is to ingest 0.3 g.kg-1 BM NaHCO3 at 60-90 minutes prior to 69 
exercise, which is based on historical research showing time to peak pH or HCO3
- occurs at 70 
this time point at the group mean level (Carr et al., 2011; Hadzic et al., 2019). It is, however, 71 
likely that through following this strategy the dissociation of NaHCO3 within stomach acid 72 
will cause gastrointestinal (GI) upset (Heibel et al., 2018), which may impair performance or 73 
dissuade athletes from using NaHCO3 (Cameron et al., 2010, Saunders et al., 2014). Whilst, 74 
some authors have observed ergogenic benefits despite moderate GI upset (Gough et al., 75 
2018, Miller et al., 2016), in some cases the upset has been severe or the participant has not 76 
been able to continue with the study procedures (Gough et al., 2017; Kahle et al., 2013). The 77 
administration of smaller NaHCO3 doses (0.2 g.kg
-1 BM) might therefore be preferable, as it 78 
can mitigate GI upset and also reduce the sodium load per dose which might alleviate the 79 
health risks of ingesting this supplement; although these risks are more associated with long 80 
term use of NaHCO3 (Gough et al., 2018; Graudal et al., 2012). McNaughton (1992) reported 81 
exacerbated GI upset following higher NaHCO3 doses, while Gough et al. (2018) observed 82 
reduced occurrence of bowel urgency and bloating for 0.2 g.kg-1 compared to 0.3 g.kg-1 BM 83 
NaHCO3. Reducing the dose is a simple strategy that might remove some of the negative 84 
connotations of ingesting this supplement, whilst it is far more cost effective than some of the 85 
recent strategies employed to reduce the GI upset following NaHCO3 ingestion, such as in 86 
enteric-coated capsules (Hilton et al., 2019; Hilton et al., 2020). 87 
Contemporary research has administered NaHCO3 using an individualised time-to-88 
peak pH or HCO3
- approach, which is in response to studies showing that time-to-peak pH or 89 
HCO3
- can vary between 10 and 180 min within individuals, regardless of the ingestion 90 
method (i.e. capsule vs. fluid) (Gough et al., 2017; Gough et al., 2018, Jones et al., 2016, 91 
Miller et al., 2016). In using the individual time-to-peak approach, this ensures that peak 92 
[HCO3
-] is achieved immediately before exercise, which does seem to lead to a more 93 
consistent ergogenic response (Gough et al., 2017; Gough et al., 2018). The identification of 94 
this time-to-peak HCO3
- response presents a logistical challenge to athletes however, as the 95 
financial cost is high and requires specialist equipment and staff. It is plausible to suggest 96 
further research is therefore required to simplify this strategy, and to assess whether 97 
ergogenic benefits still exist for smaller NaHCO3 doses following administration at a 98 
standardised time point. This, in turn, could increase the practical application of this 99 
supplement, whilst also potentially limiting GI upset. 100 
The ergogenic benefits associated with NaHCO3 ingestion are somewhat related to the 101 
increased activation of glycolytic energy pathways (da Silva et al., 2019, Lopez-Silva et al., 102 
2018). Whilst this is debated (Westerblad, 2016), NaHCO3 ingestion attenuates muscle 103 
acidosis during exercise thus preventing the allosteric inhibition of glycogen phosphorlyase 104 
and phosphofructokinase (Siegler et al., 2016). This has been shown to increase estimated 105 
glycolytic contribution during HIIT protocols (da Silva et al., 2019), while there is robust 106 
evidence suggesting enhanced glycolytic flux within the muscle (Hollidge-Horvat et al., 107 
2000). Strategies that elevate glycolytic energy system contribution may enhance exercise 108 
capacity during HIIT, however, research is yet to determine whether smaller NaHCO3 doses 109 
elicit a similar physiological response.  110 
The purpose of this study therefore was to investigate the effect of 0.2 g.kg-1 and 0.3 111 
g.kg-1 BM NaHCO3 ingested at 60 minutes pre-exercise on estimated energy contribution 112 
during a high-intensity, interval cycling test (HICT), and time-to-exhaustion (TTE) cycling 113 
performance.  114 
 115 
Materials and Methods 116 
Experimental approach to the problem 117 
A block randomised, across subjects counterbalanced, single-blind, placebo-controlled, 118 
crossover experimental design was implemented for this study. Participants visited the 119 
laboratory on four separate occasions to complete an incremental exercise test, familiarisation 120 
and three experimental trials. All testing was conducted at the same time of day (± 2 hours) to 121 
minimise the confounding effects of circadian rhythms on exercise performance (Reilly, 122 
1990). Participants arrived at the laboratory in a 3-hour post-prandial state, having refrained 123 
from alcohol ingestion and vigorous exercise for 24 hours prior. Maximal aerobic power 124 
(MAP) was determined from the incremental exercise test and used to prescribe the exercise 125 
intensities for the HICT and TTE cycling protocols (described below). Participants completed 126 
these exercise procedures for three experimental treatment arms: (a) 0.2 g.kg-1 BM NaHCO3 127 
(SBC2), (b) 0.3 g.kg-1 BM NaHCO3 (SBC3), or (c) 0.07 g.kg
-1 BM sodium chloride to ensure 128 
taste-matching (placebo; PLA) (Gough et al., 2018). Participants were instructed to maintain 129 
activity levels and dietary intake throughout the study, which were assessed via written logs. 130 
All experimental trials were separated by seven days. 131 
 132 
Participants 133 
Twelve healthy males (stature: 1.75 ± 0.08 m; body mass: 67.5 ± 6.3 kg; age: 21.0 ± 1.4 years; 134 
maximal oxygen consumption: 45.1 ± 7.0 ml.kg.min-1) volunteered for this study. All 135 
participants were recreationally active and completed at least 60 minutes of vigorous exercise 136 
per week. Participants were excluded if they had any history of hypertension (>140/80 137 
mmHg), were currently taking any medication/sports supplements, or  had ingested intra- or 138 
extracellular buffering agents within the previous 6 months. The study was approved by the 139 
institutional departmental review board. Each participant was informed of the benefits and 140 
risks of the investigation prior to signing informed consent to participate in the study. 141 
Procedures were conducted in accordance with the World Medical Association’s Declaration 142 
of Helsinki. 143 
 144 
Procedures 145 
On the initial visit, participants performed an incremental exercise test on a cycle ergometer 146 
(Excalibur Sport, Lode, Netherlands) to determine MAP. Gaseous exchange was collected 147 
using a breath-by-breath metabolic cart (Oxycon Pro, Jaeger, Hoechberg, Germany) to 148 
determine maximal rate of oxygen consumption (VO2max). To determine VO2max, the highest 149 
30 s rolling average was calculated. Following a 5-minute warm-up (70 W; 70-90 rev.min-1), 150 
increments of 20 W.min-1 were applied until volitional exhaustion. This was deemed as the 151 
failure to maintain cycling cadence >60 rev.min-1 despite verbal encouragement. Maximal 152 
anaerobic power was calculated as the fraction of time in the final stage divided by test 153 
increment, added to completed power (Pinot and Grappe, 2014). Familiarisation to exercise 154 
procedures (HICT and TTE cycling) was completed after 30 minutes of passive recovery. 155 
This involved three bouts of 60 s cycling (90%, 95% and 100% MAP), interspersed with 90 s 156 
of active recovery (100 W) and TTE cycling at 105% MAP. These were completed on the 157 
cycle ergometer, with handle bar and seat height position adjusted according to preference, 158 
which was subsequently replicated for all experimental trials. The TTE cycling protocol was 159 
terminated when cadence dropped 10 rev.min-1 below the preferred cadence, and when 160 
participants were unable to re-establish preferred cadence (range of selected cadence = 70-90 161 
rev.min-1). Participants were encouraged to exercise until volitional exhaustion, but total 162 
exercise time was not revealed.   163 
 During experimental trial visits, participants completed visual analogue scales (VAS) 164 
were used for baseline GI upset (0 mm = “no symptom”; 100 mm = “severest symptom”) that 165 
quantified the severity of nausea, flatulence, abdominal discomfort (AD), gut fullness (GF), 166 
bowel urgency rating (BUR), diarrhoea, vomiting and belching (Gough et al., 2018). 167 
Participants then consumed one of three experimental beverages (SBC2, SBC3 or PLA) 168 
across a 5-minute period 60 minutes prior to exercise. Ingestion time was chosen in-line with 169 
previous work that showed the absorption kinetics between these doses are not significantly 170 
different up to this time point (Gough et al. 2017), and is the most practiced ingestion timing 171 
(Carr et al., 2011; Hadzic et al., 2019). These were served as a chilled aqueous solution of 4 172 
ml.kg-1 BM water and 1 ml.kg-1 BM squash (double strength orange squash, Tesco, UK) to 173 
increase the palatability and taste-match each beverage (Higgins et al., 2013). A supplement 174 
belief questionnaire was completed post-ingestion to assess the efficacy of the single-blind 175 
design, and to ensure that no psychological bias regarding the impact of NaHCO3 ingestion 176 
was transferred onto participants (Gough et al., 2019). Symptoms of GI upset were repeated 177 
at 30- and 60-minutes post-ingestion. Pre-exercise capillary blood samples were collected 178 
into 20 μL end-to-end sodium heparised capillary tubes (EKF Diagnostic GmbH, Germany) 179 
and analysed for blood lactate concentration ([BLa-]) using the Biosen C-Line (EKF 180 
Diagnostic GmbH, Germany). Participants rested for 5 minutes to determine baseline oxygen 181 
consumption and respiratory exchange ratio (RER), before completing the HICT and TTE 182 
protocols, during which gaseous exchange was measured throughout, and blood samples 183 
were taken after each cycling bout. Additional visual analogue scales were completed 184 
immediately post-exercise for GI upset. An overview of experimental trials is displayed in 185 
Figure 1. 186 
 187 
[INSERT Figure 1 near here]  188 
 189 
Estimated energy system contribution calculations 190 
Absolute energy demand and energy contribution from the oxidative and glycolytic energetic 191 
systems were estimated via non-invasive technique. The oxidative phosphorylation pathway 192 
(WAER) was determined by subtracting resting oxygen consumption (i.e. the mean VO2 value 193 
during the final 30 s of baseline) from the area under the oxygen consumption curve for each 194 
of the three 60 s bouts (90%, 95% and 100% MAP) during the HICT (di Prampero and 195 
Ferretti, 1999). Area under the curve was calculated using the trapezoidal method. This 196 
approach has recently been shown to provide reliable and valid estimations for WAER during 197 
intermittent exercise (da Silva et al., 2019; Milioni et al., 2017). The glycolytic pathway 198 
(W[LA]) was calculated from the assumption that a difference of 1 mmol.l
-1 of BLa- obtained 199 
by subtracting baseline [BLa-] from peak [BLa-] (i.e. delta [BLa-]) corresponded to 3 ml.kg-1 200 
BM of O2 (Beneke et al., 2002; Brisola et al., 2015; da Silva et al., 2019; Milioni et al., 2017; 201 
Zagatto et al., 2016). Therefore, delta [BLa-] for each of the three 60 s bouts and during TTE 202 
cycling (i.e. difference from pre to post) was multiplied by 3 and the participants’ body mass 203 
to calculate W[LA]. The caloric quotient of 20.92 kJ was used to convert between absolute 204 
energy demand (in L of O2) and energy contribution (in kJ) for both energetic systems.  205 
 206 
Statistical analysis 207 
Normality and sphericity were assessed using Shapiro-Wilk and Mauchly tests, before 208 
correcting for any violations (Greenhouse Geisser). One-way repeated measures analysis of 209 
variance (ANOVA) were conducted for cycling TTE performance and total energy demand 210 
and contribution from WAER and W[LA] during exercise protocols. The smallest worthwhile 211 
change (SWC) in performance (9.1 s) was calculated as 0.3 x the between-individual SD for 212 
cycling TTE during familiarisation (Hopkins, 2004). This was then used as a threshold for 213 
interpreting individual differences and in an attempt to identify a true change in exercise 214 
performance between the NaHCO3  and the placebo conditions. Two-factor (treatment x time) 215 
repeated measures ANOVA’s were performed for [BLa-], RER, WAER and W[LA] for each of 216 
the three 60 sec bouts during the HICT. When significant interactions were observed, 217 
pairwise comparisons using the bonferroni correction factor were performed. Friedman’s 218 
two-way ANOVA’s were conducted for GI upset. Post-hoc Wilcoxon matched-pair signed 219 
rank tests were performed when significance was observed, with median, Z score and 220 
significance reported. Fisher’s exact test was used to assess the efficacy of the single-blind 221 
design. For ANOVA interactions, effect sizes were presented as partial eta-squared (ηp
2) 222 
(Olejnik and Algina, 2003). Between treatment effect sizes were calculated by dividing the 223 
difference in means by the pooled SD (Nakagawa et al., 2007), before applying a Hedges g (g) 224 
bias correction to account for the small sample size (Lakens, 2013). These were interpreted as 225 
trivial (<0.20), small (0.20–0.49), moderate (0.50–0.79), or large (0.80) (Cohen, 1988). Data 226 
are presented as mean ± SD and 95% confidence intervals (CI) reported for mean differences. 227 
Statistical significance was set at p < 0.05 and data were analysed using SPSS v25 (SPSS Inc., 228 
IBM, USA).  229 
 230 
Results 231 
Performance was greater for SBC2 (136.4 ± 43.5 s) and SBC3 (158.7 ± 63.3 s) compared to 232 
PLA (116.2 ± 46.6 s) (Figure 2). These increases were significant for SBC2 (+20.2 s; CI: 0.4, 233 
39.9; p = 0.045; g = 0.77) and SBC3 (+31.9 s; CI: 10.8, 53.1; p = 0.004; g = 1.13). A total of 234 
8 out of 12 participants improved their performance above the SWC following SBC2, whilst 235 
11 participants (out of 12) improved above this threshold following SBC3 (Figure 3). There 236 
was an 11.7 s mean difference in favour of SBC3 vs. SBC2, but this increase was not 237 
significant (p = 0.303; g = 0.48). Nonetheless, seven of the participants (out of 12) improved 238 
their performance above the SWC for SBC3 vs. SBC2, whilst this was only in favour of 239 
SBC2 for a single participant.  240 
 241 
[INSERT Figure 2-3 near here] 242 
 243 
Grouped mean ± SD data for [BLa-] and RER are presented in Table 1. No significant 244 
differences were displayed during the HICT protocol (p > 0.05). Post-TTE [BLa-] was 245 
elevated for SBC2 (+2.35 mmol.l-1; CI: 0.06, 4.64; p = 0.04; g = 0.77) and SBC3 (+3.13 246 
mmol.l-1; CI: 1.44, 4.82; p = 0.001; g = 1.40) compared to PLA. There was a small effect size 247 
for SBC3 vs. SBC2 (+0.78 mmol.l-1; p = 0.34; g = 0.46). Peak RER was also increased for 248 
SBC2 (+0.09 AU; CI: 0.03, 0.15; p = 0.005; g = 1.14) and SBC3 (+0.11 AU; CI: 0.03, 0.19; p 249 
= 0.011; g = 0.98) compared to PLA. 250 
 251 
[INSERT Table 1 near here] 252 
 253 
Total energy demand and contribution of the oxidative and glycolytic energetic 254 
systems during the HICT are presented in Table 2. No significant differences were displayed 255 
for energy demand or contribution from WAER or W[LA] (p > 0.05), although W[LA] 256 
contribution was moderately increased for SBC2 (+3.71 kJ; p = 0.09; g = 0.66) and SBC3 257 
(+7.12 kJ; p = 0.14; g = 0.60) compared to PLA (23.40 ± 8.93 kJ). There was a small effect 258 
size for W[LA] contribution when comparing SBC3 vs. SBC2 (+3.41 kJ; p = 0.99; g = 0.27). 259 
Energy contribution from WAER was greater during the second 60 s bout for PLA vs. SBC2 260 
(+4.16 kJ; CI: 0.50, 7.81; p = 0.03; g = 0.86). No significant differences were observed for 261 
energy contribution from WAER or W[LA] during TTE cycling (p > 0.05; Figure 4 A-B), 262 
although W[LA] was moderately increased for SBC2 (+7.77 kJ; p = 0.10; g = 0.65) and SBC3 263 
(+7.95 kJ; p = 0.07; g = 0.70) compared to PLA (15.62 ± 9.27 kJ). No difference was 264 
reported for W[LA] when comparing SBC3 vs. SBC2 (+0.18 kJ; p = 1.00; g = 0.01).  265 
 266 
[INSERT Table 2. near here] 267 
[INSERT Figure 4 A-B near here] 268 
 269 
Treatments were successfully single-blinded and taste-matched (Fisher’s exact test, p 270 
= 0.28). One subject identified all three beverages, eight only correctly perceived one of the 271 
three beverages, and the remaining three were unsure on all treatments. Eight participants 272 
reported their severest symptom after either SBC2 (4/12) or SBC3 (4/12), although some 273 
reported no difference between treatments (3/12), whereas one experienced the severest 274 
symptom following PLA (Table 3). No intervention or time interaction was observed at 30- 275 
or 60-minutes post-ingestion for any GI symptom (p > 0.05), or at post-exercise for vomiting, 276 
flatulence, GF, BUR or diarrhoea (p > 0.05). Nonetheless, symptom severity was increased 277 
post-exercise following SBC3 compared to PLA for nausea (10.0 mm vs. 1.0 mm; Z = -2.197; 278 
p = 0.028) and belching (8.0 mm vs. 1.0 mm; Z = -2.371; p = 0.018), but not for SBC2 279 
compared to PLA (p > 0.05). Increases in the severity of nausea post-exercise was also 280 
observed following SBC3 compared to SBC2 (Z = 2.366; p = 0.018; Figure 5A), but not 281 
belching (Z = 1.352; p = 0.176; Figure 5B). There was no difference between aggregate GI 282 
upset between SBC2 and SBC3 at any time point (all p > 0.05). 283 
 284 
[INSERT Table 2. and Figure 5 A-B near here] 285 
 286 
Discussion 287 
This study is the first to explore the dose-response effects of NaHCO3 ingestion when 288 
administered at a standardised time point on estimated energy system contribution and 289 
performance during intermittent cycling exercise. Both 0.2 g.kg-1 and 0.3 g.kg-1 BM NaHCO3 290 
improved cycling TTE and estimated glycolytic contribution during HICT, therefore both 291 
doses can be employed as an ergogenic strategy. Only minimal dose-dependent differences in 292 
GI upset were observed, although the smaller dose mitigated severity of post-exercise nausea 293 
and belching. The key finding of this study therefore is that 0.2 g.kg-1 BM of NaHCO3 can 294 
increase estimated glycolytic system contribution and be ergogenic for intermittent exercise 295 
performance.  296 
Improvements in cycling TTE were observed for SBC2 and SBC3, with the moderate-297 
to-large effect sizes reflective of previous findings employing a similar TTE protocol 298 
(Higgins et al., 2013). The present study adds to previous work (McKenzie et al., 1986; 299 
McNaughton, 1992), however, that ergogenic benefits can also be observed with a lower dose 300 
of NaHCO3. Importantly, however, more participants improved over the SWC for SBC3 vs. 301 
SBC2, and a small effect size between treatments was observed in favour of SBC3 at the 302 
group level. This contradicts findings by McKenzie et al. (1986) that displayed a 4 s 303 
difference in TTE for 0.15 g.kg-1 and 0.3 g.kg-1 BM NaHCO3, and Gough et al. (2018) where 304 
only a 0.1% variation in 4-km cycling time trial performance was present for 0.2 g.kg-1 and 305 
0.3 g.kg-1 BM doses. This discrepancy could be explained by differences in administration 306 
approach (standardised time point vs. time-to-peak), or the high-degree of inter-individual 307 
variation present in acid base balance following NaHCO3 ingestion. Nonetheless, based on 308 
seven participants improving their performance following SBC3 vs. SBC2 (based on SWC), 309 
it is likely the athlete will secure the largest benefit from this higher dose. These dose-310 
dependent differences in performance could also be attributed to the timing of exercise 311 
protocols. The cycling TTE protocol commenced ~75 minutes after NaHCO3 ingestion 312 
accounting for both the warm-up and HICT, however it is expected that [HCO3
-] will 313 
continue to rise until ~80 minutes post-ingestion for SBC3, by which point [HCO3
-] will have 314 
started to decline for SBC2 in most individuals (Gough et al., 2017, Gough et al., 2018). 315 
Nonetheless, athletes unable to pre-determine their time-to-peak HCO3
- can still employ 316 
either dosing strategy of the present study to obtain performance benefits during high-317 
intensity cycling exercise. 318 
Moderate, albeit non-significant, increases were observed for W[LA] during the HICT 319 
without altering energy demand or contribution from WAER, which is in agreement to findings 320 
from recent studies (Brisola et al., 2015; da Silva et al., 2019; Lopes-Silva et al., 2018). 321 
Despite not achieving statistical significance, these increases were considered substantial for 322 
both SBC2 (+15.8%) and SBC3 (+30.3%) when compared to PLA, with the relatively small 323 
absolute changes in W[LA] attributed to the controlled total mechanical work during the HICT 324 
(da Silva et al., 2019). The most novel finding, however, was that there may be a dose-325 
response effect of NaHCO3 ingestion on changes in energy system contributions, with a small 326 
effect size present for W[LA] in favour of SBC3. Considering that enhanced HCO3
- buffering 327 
capacity is responsible for elevating glycolytic contribution, one explanation for these dose-328 
dependent results could relate to the total amount of H+ that can be neutralised. Assuming 329 
that total blood volume is ~5 L and that [HCO3
-] was as small as ~1.0 mmol.l-1 higher for 330 
SBC3 vs. SBC2, then the higher dose could have allowed the neutralisation of an extra ~5 331 
mmoles of H+ (based on the 1:1 stoichiometry of HCO3
- and H+ reaction), in theory eliciting a 332 
greater up-regulation of glycolytic contribution (da Silva et al., 2019). It is important to note, 333 
however, that as the current methodology only indirectly assesses glycolytic flux (i.e. from 334 
changes in [BLa-]), these increases in W[LA] contribution may overestimate glycolytic 335 
activation, instead reflecting greater lactate efflux from working muscles (Siegler et al., 336 
2016). Nonetheless, previous research has corroborated the findings of the present study 337 
following NaHCO3 ingestion (Hollidge-Horvat et al., 2000), therefore it seems plausible that 338 
both dosing strategies partially up-regulate glycolytic activation during high-intensity 339 
cycling. 340 
The ingestion of NaHCO3 resulted in mild-to-moderate GI symptoms, although both 341 
doses were well tolerated, which agrees with previous research (Gough et al., 2017). Minimal 342 
dose-dependent differences were observed for GI upset, though the reduced post-exercise 343 
nausea and belching for SBC2 agrees with Gough et al. (2018) where belching was 344 
exacerbated for the higher dose. The reduced severity of GI upset from this study could be 345 
attributed to the body mass of the participants in the present study (mean = 68 ± 6 kg) 346 
compared to those that have reported greater severity of GI upset in healthy males (Kahle et 347 
al., 2013) and trained rugby players (Cameron et al., 2013) (90 ± 6 and 95 ± 13 kg). Relative 348 
dosing protocols were derived during early laboratory studies to normalise post-exercise base 349 
deficit (Singer et al., 1955), and therefore fail to account for physiological differences such as 350 
body mass and the total absolute NaHCO3 dose. Athletes with high body mass administer a 351 
greater absolute NaHCO3 dose despite minimal differences in gut absorption rates, 352 
particularly for the first 60 min post-ingestion (Gough et al. 2017), which most likely 353 
exacerbates GI upset. There might be an upper threshold for absolute NaHCO3 doses, with 354 
doses above this exacerbating GI upset. At present, 0.2 g.kg-1 BM NaHCO3 is a suitable 355 
strategy for mitigating GI upset; however, future research could examine the effect of 356 
absolute dosage on symptom severity and exercise performance.  357 
There are methodological limitations in the present study that future research should 358 
address. Firstly, the single-blind design of this study is a limitation that is important to note. 359 
Important methodological choices were adopted, however, to mitigate any potential impact of 360 
this design. This included the standardised verbal encouragement during exercise, and the use 361 
of a supplement belief questionnaire, as per previous research (Gough et al., 2018). The 362 
findings from the latter methodological decision suggested that the supplement was blinded 363 
from the participants and therefore the single-blind design has no impact on the efficacy of 364 
NaHCO3 ingestion. Moreover, our inability to quantify changes in absolute demand and 365 
contribution from the ATP-PCr energetic system is a limitation. This was due to the relatively 366 
short recovery period (90 s) between each bout of the HICT that did not allow a clear EPOC 367 
curve to form and therefore, it was decided that the ATP-PCr energy contribution calculations 368 
should be excluded from our analysis. Lastly, it was not possible to measure changes in 369 
[HCO3
-] following NaHCO3 ingestion in the present study. Evidence suggests, however, that 370 
the HCO3
- response is similar for 0.2 g.kg-1 and 0.3 g.kg-1 BM NaHCO3 doses within ~60 371 
mins, therefore participants were likely at a similar level of alkalosis irrespective of dose 372 
(Gough et al., 2017; Gough et al., 2018). This timing of NaHCO3 ingestion employed in this 373 
study was selected to assess of the potential ergogenic effects for athletes unable to adopt an 374 
individualised time-to-peak HCO3
- approach, or access a blood gas analyser. Based on the 375 
observed ergogenic benefits for both doses vs. PLA, it should further enhance the practical 376 
application of NaHCO3 supplementation to the athlete with limited funding.  377 
 378 
Conclusion 379 
Ingestion of 0.2 g.kg-1 and 0.3 g.kg-1 BM elevated glycolytic contribution to high intensity 380 
exercise and are ergogenic strategies to improve exercise performance. It is likely that 381 
athletes will gain increased benefit from SBC3, despite the occurrence of higher GI upset. 382 
Nonetheless, some athletes may still opt for the lower dose if this displays greater tolerability, 383 
whilst still securing an ergogenic benefit. The present study also shows that the contemporary 384 
time to peak alkalosis strategy might not be required when ingested 60 min prior to exercise, 385 
however direct comparisons between these two methods of ingestion are required.  386 
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 397 
Contribution to the field statement  398 
Recently a contemporary approach to sodium bicarbonate supplementation has been mooted 399 
as the optimal way to obtain improvements in exercise performance. This approach requires 400 
complex, expensive kit and specialist knowledge of blood biochemistry, however, and so it is 401 
unlikely to be available to many athletes. The purpose of this study therefore was to re-402 
explore traditional options to assess if athletes could gain the improvements in performance 403 
without this outlay. Equally, lower doses of sodium bicarbonate have been shown to provide 404 
benefits to exercise performance to a similar extent than higher doses of the supplement. This 405 
is important as lower doses typically lead to less negative side effects (e.g. stomach ache, 406 
vomiting), and have a lower total sodium load per dose. The present study showed that both 407 
doses of sodium bicarbonate lead to improvements in performance, although it is likely that 408 
the higher dose will offer a greater improvement. Nonetheless, we have shown that athletes 409 
and coaches can use this strategy instead of opting for the more scientific approach, yet still 410 
achieve improvements to performance. This may subsequently improve the use of sodium 411 
bicarbonate supplementation in a practical setting, and make this more attractive to the athlete 412 
that has limited funding.  413 
 414 
Figure legends 415 
Figure 1. Schematic overviewing procedures during experimental visits; MAP – maximal 416 
aerobic power; TTE – time to exhaustion. 417 
 418 
Figure 2. Mean differences and inter-individual variation for TTE cycling performance; 419 
SBC2 – 0.2 g.kg-1 BM NaHCO3; SBC3 – 0.3 g.kg
-1 BM NaHCO3; PLA – sodium chloride 420 
(placebo); * sig difference compared to PLA trial (p < 0.05). 421 
 422 
Figure 3. Individual changes (with mean; clear bar) in TTE duration compared to PLA 423 
condition; SBC2 – 0.2 g.kg-1 BM NaHCO3; SBC3 – 0.3 g.kg
-1 BM NaHCO3; PLA – sodium 424 
chloride (placebo); dashed horizontal line depicts SWC in performance (9.1 s). 425 
 426 
Figure 4 A-B. Mean ± SD for WAER (A) and W[LA] (B) contribution during TTE cycling; 427 
SBC2 – 0.2 g.kg-1 BM NaHCO3; SBC3 – 0.3 g.kg
-1 BM NaHCO3; PLA – sodium chloride 428 
(placebo).  429 
 430 
Figure 5 A-B. Inter-individual variations in post-exercise nausea and belching; self-reported 431 
symptoms via visual analogue scales (out of 100 mm); SBC2 – 0.2 g.kg-1 BM NaHCO3; 432 
SBC3 – 0.3 g.kg-1 BM NaHCO3; PLA – sodium chloride (placebo).  433 
 434 
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